



PROFESSIONAL  
BRAND

# SANI-HANDS™

Made with  
**TENCEL®**

technical data bulletin



## PRODUCT DESCRIPTION

Nonwoven cloth saturated with ethyl alcohol gel solution for the antiseptic cleansing of hands. Solution and towel are fragrance-free and dye-free.

## CHEMICAL COMPOSITION

### Active Ingredients

- Active Ingredients:
  - Alcohol (Ethanol).....65.9% by volume

### Inactive Ingredients

Water, Propylene glycol, Glycerin, Aloe barbadensis leaf juice, Tocopheryl acetate (Vitamin E)

## EFFICACY

### IN-VITRO TIME KILL STUDIES

**Purpose** - To determine how rapidly and effectively Sani-Hands® killed a variety of Gram negative and Gram positive microorganisms including spore forming bacteria at a 15-second exposure.

**Methodology** - Fluid from the wipe was expressed aseptically and transferred to sterile incubator tubes. The tubes were subsequently inoculated with the broth culture of each test microorganism containing up to 10<sup>8</sup> CFU. After 15 seconds, the entire inoculated volume of Sani-Hands® was transferred to neutralizers. Serial dilutions were plated using standard plating techniques, and percent reductions for each organism were calculated after incubation.

**Conclusion** - Sani-Hands® demonstrated to be very effective at killing all 30 microorganisms listed inside in 15 seconds (see Chart 1, page 2).

*Independent Laboratory: Mycoscience Labs, Willington, CT; June 28, 2004*



PROFESSIONAL®

wipe your world clean™



## VIRAL STUDIES\*

**Purpose** – To evaluate the antiviral properties of Sani-Hands® when exposed to a virus (in suspension) for a 15-second exposure.

**Methodology** – Fluid from the wipe was expressed aseptically and transferred to sterile tubes. The tubes were subsequently inoculated with the virus suspension and held for the 15-second exposure period. After the exposure period, a small aliquot was removed and assayed for presence of virus.

**Conclusion** – In the presence of 5% fetal bovine serum, Sani-Hands® demonstrated a greater than 99% reduction in viral titer after the 15-second exposure period against the viruses listed (see Chart 2).

*Independent Laboratory: ATS Labs, Eagan, MN: June 28, 2004*

## IN-VIVO

### HEALTHCARE PERSONNEL HANDWASH STUDY USING SOILED HANDS

**Purpose** – To demonstrate the functionality of mechanical wiping relative to microbial reduction on heavily soiled hands.

**Methodology** – The protocol used in this study is based on the procedures prescribed in the 1994 FDA Tentative Final Monograph for healthcare personnel handwash (*Federal Register*, Vol. 59, pp. 31402-31452, June 17, 1994). This procedure was modified to assess the effects of heavily soiled hands by using raw beef with a Gram negative bacteria (*E. coli*) count of at least  $10^6$  CFU/gram. Sani-Hands® was tested against a rub-in alcohol handwash gel and a non-active control (wipe, wet with sterile water). Each subject followed a treatment procedure aligned with label use instructions.

**Conclusion** – The performance criteria defined in the 1994 FDA Tentative Final Monograph, in part, requires that a product achieve at least a  $\geq 2.0 \log_{10}$  reduction in a marker organism after the first treatment application. Sani-Hands® achieved  $>2.0 \log_{10}$  reduction after a single hand treatment, thus exceeding FDA efficacy performance criteria specified for the initial treatment. The data at right (Chart 3) suggests that the superior performance of Sani-Hands® is enhanced by the physical removal of soil and bacteria by the wipe. The results of the non-active control clearly demonstrate that physical wiping is functional in reducing microbial population. Even without the

## CHART 1: Percent Reduction After 15-Second Exposure

Microorganism	Classification	ATCC#	% Reduction
<i>Acinetobacter baumannii</i> , (multi-drug resistant)	Gram negative rod	19606	>99.999
<i>Aspergillus flavus</i>	fungi (mold)	9643	=99.999
<i>Bacillus megaterium</i>	Gram positive bacteria	14581	>99.999
<i>Campylobacter jejuni</i>	Gram negative rod	29428	>99.999
<i>Candida albicans</i>	fungi (yeast)	14053	>99.999
<i>Clostridium difficile</i>	Gram positive bacteria	9689	>99.998
<i>Corynebacterium diphtheriae</i>	Gram positive rod	11913	>99.999
<i>Enterobacter aerogenes</i>	Gram negative rod	13048	>99.999
<i>Enterococcus faecium</i> (multi-drug resistant including Vancomycin)	Gram positive cocci	51559	>99.999
<i>Enterococcus faecalis</i> (Vancomycin, Streptomycin, and Gentamicin resistant)	Gram positive cocci	51575	>99.999
<i>Escherichia coli</i> (ESBL producing, (multi-drug resistant, derived from clinical isolate, Klebsiella pneumoniae ATCC #14714)	Gram negative rod	BAA-196	>99.999
<i>Escherichia coli</i>	Gram negative rod	11229	>99.999
<i>Escherichia coli</i> (O157:H7)	Gram negative rod	35150	>99.999
<i>Escherichia coli</i> (O111:H8)	Gram negative rod	BAA-184	>99.999
<i>Klebsiella pneumoniae</i>	Gram negative rod	13883	>99.99
<i>Klebsiella pneumoniae</i> (carbapenem resistant)	Gram negative rod	BAA-1705	>99.999
<i>Listeria monocytogenes</i>	Gram positive rod	15313	>99.999
<i>Proteus mirabilis</i>	Gram negative rod	7002	>99.999
<i>Proteus hauseri</i> ( <i>vulgaris</i> )	Gram negative rod	13315	>99.999
<i>Pseudomonas aeruginosa</i>	Gram negative rod	15442	>99.999
<i>Salmonella choleraesuis</i> <i>serotype typhimurium</i>	Gram negative rod	14028	>99.999
<i>Serratia marcescens</i>	Gram negative rod	14756	>99.999
<i>Shigella sonnei</i>	Gram negative rod	11060	>99.999
<i>Staphylococcus aureus</i> (MRSA)	Gram positive cocci	33591	>99.999
<i>Staphylococcus aureus</i> (MRSA, Vancomycin tolerant)	Gram positive cocci	700788	>99.999
<i>Staphylococcus epidermidis</i>	Gram positive cocci	12228	>99.999
<i>Streptococcus pneumoniae</i>	Gram positive cocci	33400	>99.999
<i>Streptococcus pyogenes</i>	Gram positive cocci	19615	>99.999
<i>Trichophyton mentagrophytes</i>	fungi (mold)	9533	>99.999
<i>Vibrio parahaemolyticus</i>	Gram negative rod	17802	>99.999

**CHART 2: Percent Reduction After 15-Second Exposure**

Virus	ATCC#	% Reduction
<i>Herpes simplex virus type 1, Strain F(1)</i>	VR-733	>99.000
<i>Human Coronavirus, Strain 229E</i>	VR-740	>99.000
<i>Influenza A virus, Strain Hong Kong</i>	VR-544	>99.000
<i>Rhinovirus type 16, Strain 11757</i>	VR-1126	>99.000
<i>HIV-1 (AIDS Virus) Strain HTLV-III<sub>g</sub></i>	—	>99.990
<i>Rotavirus, Strain WA (University of Ottawa)</i>	—	>99.000

\* The 1994 FDA Tentative Final Monograph does not comment on viral efficacy of hand hygiene products.

(continued from previous page)

presence of an antimicrobial, the non-active control achieved nearly a 2 log<sub>10</sub> reduction. The data further suggests that, with the rub-in alcohol handwash gel, there is a significant disadvantage in microbial reduction without the benefit of wiping action.

Independent Laboratory: Hill Top Research, Inc., Miamiville, OH: November 30, 2004

**HEALTHCARE PERSONNEL HANDWASH STUDY**

**Purpose** – To determine the ability of Sani-Hands® to give reduction of transient microbial flora when used in a hand treatment procedure with marker organism, *Serratia marcescens* ATCC No. 14752.

**Methodology** – The protocol used in this study is based on the procedures prescribed in the 1994 FDA Tentative Final Monograph for healthcare personnel handwash (*Federal Register*, Vol. 59, pp. 31402-31452, June 17, 1994). The required procedure is a modification of ASTM E-1174-94. Each subject followed a treatment procedure aligned with label use instructions.

**Conclusion** – Sani-Hands® achieved >2.0 log<sub>10</sub> reduction after a single hand treatment, thus exceeding FDA efficacy performance criteria for the initial treatment.

Independent Laboratory: Hill Top Research, Inc., Miamiville, OH: September 30, 2004

**SAFETY**

**REPEATED INSULT PATCH TEST**

**Purpose** – To determine the dermal irritation and sensitization potential of Sani-Hands®

**Methodology** – Study was conducted using 216 subjects. The induction phase involved repeated exposure of the product at the same site on each subject three times a week for a total of nine applications. Ten to 14 days after induction, a challenge patch was applied to a virgin site on each subject for 24 hours.

**CHART 3: Results from Health Care Personnel Handwash Study Using Soiled Hands**

PRODUCT	LOG <sub>10</sub> REDUCTION
Sani-Hands® (alcohol gel wipe)	2.70
Non-Active Control (wipe, wet with sterile water)	1.95
Rub-In Alcohol Handwash Gel	1.57

After 24 hours, the patch was removed and the site was evaluated for dermal irritation.

**Conclusion** – Sani-Hands® demonstrated minimal or no reaction which would cause dermal irritation or sensitization.

Independent Laboratory: Clinical Research Laboratories, Piscataway, NJ: June 11, 2004

**SAFETY IN-USE**

**Purpose** – To evaluate the dermal irritation potential of Sani-Hands® under exaggerated use conditions following 25 repeated uses.

**Methodology** – A total of 25 human subjects completed the study. Each subject used one wipe on both hands for approximately 30 seconds. This was repeated 25 times with 5-minute intervals between uses. Subjects hands were evaluated at the end of 25 uses.

**Conclusion** – Sani-Hands® did not demonstrate any potential for eliciting dermal irritation in any of the 25 human subjects.

Independent Laboratory: Clinical Research Laboratories, Piscataway, NJ: May 13, 2004

## OTHER INFORMATION & TESTING

---

### Skin Moisturization

Sani-Hands® contains several emollients, such as, glycerin, propylene glycol, aloe and Vitamin E acetate to promote moisturization of skin and help minimize the drying effect of alcohol.

### OSHA Bloodborne Pathogen Standard 29 CFR Part 1910.1030

Meets the specific handwashing standard 1910.1030 (d)(2)(iv).

### FDA Food Code Compliant

Meets the Food and Drug Administration (FDA) Food Code, Section 2-301.16.

### CHG Compatibility

A laboratory study was conducted to determine the effects of Chlorhexidine Gluconate (CHG) when combined directly with the Sani-Hands® solution. The study was based on the equivalent of using ten applications of Sani-Hands® and one application of a 3.0% CHG product. Results showed that Sani-Hands® did not cause significant reduction of percent CHG, and would therefore, not adversely affect the persistent activity of CHG containing products.

### Glove Use

It is recommended to allow hands to dry completely after using Sani-Hands® prior to applying gloves.

### Shelf Life

FDA-OTC stability was conducted for purposes of establishing an expiration date for the unopened product. Current stability data supports a two-year expiration period from date of manufacture.

## WARNINGS

---

- **Flammable, keep away from fire or flame.**
- **For external use only.**
- Do not use in or contact the eyes.
- Discontinue use if irritation and redness develop.
- If condition persists for more than 72 hours consult a physician.